Hybio Pharmaceutical Co., Ltd. (300199.SZ)
CNY 13.0
(4.17%)
CNY 13.0
(4.17%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 152.59 Million CNY | -19.67% |
| 2022 | 189.95 Million CNY | 20.89% |
| 2021 | 157.13 Million CNY | -15.86% |
| 2020 | 186.76 Million CNY | 22.87% |
| 2019 | 152 Million CNY | -5.95% |
| 2018 | 161.61 Million CNY | 13.17% |
| 2017 | 142.81 Million CNY | 4.56% |
| 2016 | 136.58 Million CNY | 12.86% |
| 2015 | 121.02 Million CNY | 149.21% |
| 2014 | 48.56 Million CNY | 71.71% |
| 2013 | 28.28 Million CNY | 28.45% |
| 2012 | 22.01 Million CNY | 33.9% |
| 2011 | 16.44 Million CNY | -1.48% |
| 2010 | 16.68 Million CNY | -7.84% |
| 2009 | 18.11 Million CNY | 34.24% |
| 2008 | 13.49 Million CNY | -11.1% |
| 2007 | 15.17 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 250.19 Million CNY | 24.8% |
| 2024 Q1 | 151.52 Million CNY | -0.7% |
| 2024 Q2 | 200.47 Million CNY | 32.31% |
| 2023 Q2 | 208.05 Million CNY | -0.3% |
| 2023 Q3 | 200.22 Million CNY | -3.76% |
| 2023 FY | 152.59 Million CNY | -19.67% |
| 2023 Q4 | 152.59 Million CNY | -23.79% |
| 2023 Q1 | 208.67 Million CNY | 9.85% |
| 2022 Q1 | 175.35 Million CNY | 11.59% |
| 2022 Q4 | 189.95 Million CNY | -14.09% |
| 2022 Q2 | 204.26 Million CNY | 16.49% |
| 2022 FY | 189.95 Million CNY | 20.89% |
| 2022 Q3 | 221.1 Million CNY | 8.24% |
| 2021 Q3 | 201.49 Million CNY | 6.35% |
| 2021 Q1 | 171.81 Million CNY | -8.0% |
| 2021 Q2 | 189.46 Million CNY | 10.27% |
| 2021 FY | 157.13 Million CNY | -15.86% |
| 2021 Q4 | 157.13 Million CNY | -22.01% |
| 2020 Q4 | 186.76 Million CNY | -7.65% |
| 2020 FY | 186.76 Million CNY | 22.87% |
| 2020 Q1 | 165.49 Million CNY | 8.87% |
| 2020 Q2 | 208.67 Million CNY | 26.09% |
| 2020 Q3 | 202.23 Million CNY | -3.08% |
| 2019 FY | 152 Million CNY | -5.95% |
| 2019 Q1 | 193 Million CNY | 19.42% |
| 2019 Q2 | 176.84 Million CNY | -8.37% |
| 2019 Q3 | 187.64 Million CNY | 6.11% |
| 2019 Q4 | 152 Million CNY | -18.99% |
| 2018 Q4 | 161.61 Million CNY | -18.2% |
| 2018 FY | 161.61 Million CNY | 13.17% |
| 2018 Q3 | 197.58 Million CNY | 14.28% |
| 2018 Q2 | 172.89 Million CNY | 9.39% |
| 2018 Q1 | 158.05 Million CNY | 10.67% |
| 2017 Q2 | 137.64 Million CNY | 5.89% |
| 2017 Q1 | 129.98 Million CNY | -4.83% |
| 2017 FY | 142.81 Million CNY | 4.56% |
| 2017 Q4 | 142.81 Million CNY | -0.97% |
| 2017 Q3 | 144.21 Million CNY | 4.77% |
| 2016 FY | 136.58 Million CNY | 12.86% |
| 2016 Q2 | 138.66 Million CNY | 3.38% |
| 2016 Q1 | 134.13 Million CNY | 10.83% |
| 2016 Q3 | 141.61 Million CNY | 2.12% |
| 2016 Q4 | 136.58 Million CNY | -3.55% |
| 2015 Q3 | 117.41 Million CNY | 6.18% |
| 2015 Q1 | 97.7 Million CNY | 101.2% |
| 2015 FY | 121.02 Million CNY | 149.21% |
| 2015 Q4 | 121.02 Million CNY | 3.07% |
| 2015 Q2 | 110.58 Million CNY | 13.18% |
| 2014 Q3 | 50.02 Million CNY | 9.14% |
| 2014 FY | 48.56 Million CNY | 71.71% |
| 2014 Q1 | 36.81 Million CNY | 30.17% |
| 2014 Q4 | 48.56 Million CNY | -2.92% |
| 2014 Q2 | 45.83 Million CNY | 24.49% |
| 2013 Q2 | 25.88 Million CNY | 5.47% |
| 2013 FY | 28.28 Million CNY | 28.45% |
| 2013 Q4 | 28.28 Million CNY | -6.6% |
| 2013 Q3 | 30.28 Million CNY | 17.0% |
| 2013 Q1 | 24.53 Million CNY | 11.45% |
| 2012 Q4 | 22.01 Million CNY | -8.24% |
| 2012 FY | 22.01 Million CNY | 33.9% |
| 2012 Q1 | 18.14 Million CNY | 10.38% |
| 2012 Q2 | 21.65 Million CNY | 19.32% |
| 2012 Q3 | 23.99 Million CNY | 10.81% |
| 2011 Q4 | 16.44 Million CNY | -15.11% |
| 2011 Q2 | 16.11 Million CNY | -5.99% |
| 2011 Q1 | 17.13 Million CNY | 2.68% |
| 2011 Q3 | 19.36 Million CNY | 20.23% |
| 2011 FY | 16.44 Million CNY | -1.48% |
| 2010 Q2 | 17.61 Million CNY | 0.0% |
| 2010 FY | 16.68 Million CNY | -7.84% |
| 2010 Q4 | 16.68 Million CNY | 0.0% |
| 2009 FY | 18.11 Million CNY | 34.24% |
| 2008 FY | 13.49 Million CNY | -11.1% |
| 2007 FY | 15.17 Million CNY | 0.0% |